[Inhibition of ketogenesis in liver tissue by tolbutamide and glycodiazine in vitro].
D000085:Acetates / Q000378:metabolism; D000090:Acetoacetates / Q000096:biosynthesis*; D000818:Animals; D002247:Carbon Isotopes; D003864:Depression, Chemical; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism; D016883:Diabetic Ketoacidosis / Q000209:etiology; D005215:Fasting; D006885:Hydroxybutyrates / Q000096:biosynthesis*; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D066298:In Vitro Techniques; D007657:Ketone Bodies / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D010169:Palmitic Acids / Q000378:metabolism; D051381:Rats; D013449:Sulfonamides / Q000494:pharmacology; D014044:Tolbutamide / Q000494:pharmacology*
D000085:Acetates; D000090:Acetoacetates; D002247:Carbon Isotopes; D006885:Hydroxybutyrates; D007004:Hypoglycemic Agents; D007657:Ketone Bodies; D010169:Palmitic Acids; D013449:Sulfonamides; D014044:Tolbutamide
Die Hemmung der Ketogenese im Lebergewebe durch Tolbutamid und Glykodiazin in vitro.